• Tomoe Nishihara, Hiroshi Nakano, Hiroko Nogami, Katsuyuki Katahira, Akiko Ishimatsu, Naozumi Hashimoto, Toyoharu Yokoi, and Tomoaki Iwanaga.
• Department of Psychosomatic Medicine, National Hospital Organization, Fukuoka National Hospital, Fukuoka, Japan; Department of Psychosomatic Medicine, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
• Chest. 2017 Mar 1; 151 (3): e57-e62.

Case PresentaionA 63-year-old woman visited our hospital for a further evaluation of progressive dyspnea. She had developed a progressive airflow obstruction after 3 years' remission of non-Hodgkin's lymphoma (follicular mixed cell type), which had been treated with chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). The patient's primary care physician had diagnosed her as having COPD and bronchial asthma and had treated her with medications including inhaled corticosteroids, tiotropium, and oral erythromycin. Her dyspnea had gradually worsened, however, and she had a score of 4 on the modified Medical Research Council dyspnea scale at the time of admission to our hospital.Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

43 keywords...

hide…